letter to the editor - Annals of Oncology

letter to the editor
respect to long-term data to learn all the details with respect to
effectiveness. I do not, however, concur with their negative and
unsubstantiated statement claiming this analysis fails with
respect to assumptions and interpretation of results.
E. Lonning*
Institute of Medicine Haukeland University Hospital, Department of
Oncology, Bergen, Norway
(*E-mail: per.lonning@helse-bergen.no)
references
1. Delea TE, Karnon J, Goss PE. Conclusions regarding relative cost-utility of
alternative strategies for use of aromatase inhibitors in postmenopausal women with
early breast cancer are premature. Ann Oncol; doi:10.1093/annonc/mdl171.
2. Lønning PE. Comparing cost/utility of giving an aromatase inhibitor as
monotherapy for 5 years versus sequential administration following 2–3 or 5
years of tamoxifen as adjuvant treatment for postmenopausal breast cancer. Ann
Oncol 2006; 17: 217–225.
3. Geisler J, Haynes B, Anker G, Dowsett M, Lønning PE. Influence of letrozole
(Femara) and anastrozole (Arimidex) on total body aromatization and plasma
estrogen levels in postmenopausal breast cancer patients evaluated in
a randomized, cross-over-designed study. J Clin Oncol 2002; 20: 751–757.
4. Johannessen DC, Engan T, Salle ED et al. Endocrine and clinical effects of
exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in
postmenopausal breast cancer patients: a phase I study. Clin Cancer Res 1997;
3: 1101–1108.
2 | letter to the editor
5. Lønning PE, Bajetta E, Murray R et al. Activity of exemestane in metastatic breast
cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin
Oncol 2000; 18: 2234–2244.
6. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on
bone mineral density measured by dual-energy X-ray absorptiometry in
healthy premenopausal and postmenopausal women. J Clin Oncol 1996;
14: 78–84.
7. Perez EA, Josse RG, Pritchard KI et al. Effect of letrozole versus placebo on
bone mineral density in women completing >5 years (yrs) of adjuvant
tamoxifen: ncic ctg ma.17b. Breast Cancer Res Treat 2004; 88 (Suppl 1):
Abstr 404, s36.
8. Lønning PE, Geisler J, Krag LE et al. Effects of exemestane administered for 2
years versus placebo on bone mineral density, bone biomarkers, and plasma
lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005;
23: 5126–5137.
9. Geisler J, Lønning PE. Aromatase inhibitors as adjuvant treatment of breast
cancer. Crit Rev Oncol Hematol 2006; 57: 53–61.
10. Group EBCTC. Effects of chemotherapy and hormonal therapy for early breast
cancer on recurrence and 15-year survival: an overview of the randomised trials.
Lancet 2005; 365: 1687–1717.
11. Nordenskjold B, Rosell J, Rutqvist LE et al. Coronary heart disease mortality after
5 years of adjuvant tamoxifen therapy: Results from a randomized trial. Journal of
the National Cancer Institute 2005; 97: 1609–1610.
12. Anderson GL, Limacher M, Assaf AR et al. Effects of conjugated, equine
estrogen in postmenopausal women with hysterectomy. The women’s
health initiative randomized controlled trial. JAMA 2004; 291:
1701–1712.
doi:10.1093/annonc/mdl170
Annals of Oncology
Downloaded from
http://annonc.oxfordjournals.org/ by guest on July 19, 2013